About

Science

Pipeline

Investor Information

Contact Us

Investor Information

Investor Information

Press Releases

Feb 10, 2020 2:48 PM EST Can-Fite BioPharma Announces Pricing of $5 Million Public Offering
Feb 3, 2020 7:30 AM EST Can-Fite Completes 50% Patient Enrollment in Phase III Rheumatoid Arthritis Study & Implements Interim Analysis
Jan 16, 2020 7:00 AM EST Can-Fite and Univo Pharmaceuticals Collaboration Result in Discovery and Applied Patent for Cannabinoid Formulations with Broad Therapeutic Effects
Jan 9, 2020 9:10 AM EST Can-Fite Announces Exercise of Warrants for Cash Proceeds of $2.4 Million
Jan 7, 2020 8:20 AM EST Data from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer
Jan 6, 2020 7:00 AM EST Can-Fite CEO Issues Letter to Shareholders
Jan 3, 2020 7:00 AM EST New Data From Hadassah Medical Center Lab Show Can-Fite’s Namodenoson Induces Weight Loss
Dec 26, 2019 7:00 AM EST Golan Bitton Univo Pharmaceutical CEO Elected to the Can-Fite Board: A Strategic Partnership with Univo to Develop Cannabinoid-Based Products is Ongoing
Dec 9, 2019 8:15 AM EST Can-Fite Completes 50% Patient Enrollment in its Phase III Psoriasis Trial
Dec 5, 2019 7:00 AM EST Can-Fite to Attend BioFIT 2019 Conference in Europe with Focus on Partnering Meetings for Namodenoson in NASH

<< Previous
1
2
3
4
5
6
7
8
9
10
...30
Next >>

Show All